Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Key Highlights
- ➤$289.4 million cash funds operations into the second half of 2028
- ➤ASCEND dose escalation completed after more than 125 patients dosed globally
- ➤Initial CR-001 monotherapy data, including first-line NSCLC responses, expected Q1 2027
- ➤CR-002 global APOLLO trial began dosing; initial data expected in second half of 2027
- ➤Third-quarter net loss widened to $37.7 million from $24.6 million year over year
Expert Statements
Joshua Brumm, Chief Executive Officer of Crescent Biopharma
“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027. We plan to aggressively pursue additional combination opportunities that can further our efforts to develop CR-001 as a best-in-class IO backbone therapy. Building on the pipeline progress we outlined last month, we are pleased to have now commenced patient dosing in the global APOLLO trial of CR-002, our PD-L1-targeted ADC”
Joshua Brumm, Chief Executive Officer of Crescent Biopharma
“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types. We are poised for an exciting year ahead as we work to deliver the next wave of therapies for people living with cancer.”
Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027
Multiple Phase 2 studies of sacituzumab tirumotecan (sac-TMT) in combination with CR-001 ongoing in China led by partner, Kelun-Biotech, with initial data in NSCLC expected in mid-2027; additional antibody-drug conjugate (ADC) combinations planned; partnership achieved 9 IND clearances this year
Get started
Create a free account to read the full story.